( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 131 | アレキサンダー病 | 4 |
131. アレキサンダー病
臨床試験数 : 4 / 薬物数 : 4 - (DrugBank : 1) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
Showing 1 to 4 of 4 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-000976-40-IT (EUCTR) | 07/10/202120211007 | 02/08/202120210802 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients withAlexander Disease Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Admin ... | A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics ofIntrathecally Administered ION373 in Patients with Alexander Disease - NA A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Ph ... | Alexander Disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, familial and genetic disorders;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Alexander Disease MedDRA version: 20.0;Level: SOC;Classification code 10010331;Term: Congenital, fam ... | Product Name: ION373 Product Code: [ION373] INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING Product Name: ION373 Product Code: [ION373] INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2 ... | IONIS PHARMACEUTICALS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 1;Phase 2;Phase 3 | United States;Canada;Argentina;Australia;Israel;Netherlands;United Kingdom;Japan;Italy | ||
| 2 | NCT04849741 (ClinicalTrials.gov) | June 1, 202120210601 | 16/4/202120210416 | A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD) | A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Ph ... | Alexander Disease | Drug: ION373;Drug: Placebo | Ionis Pharmaceuticals, Inc. | NULL | Recruiting | 2 Years | 65 Years | All | 73 | Phase 3 | United States;Australia;Canada;Israel;Italy;Japan;Netherlands;United Kingdom |
| 3 | EUCTR2020-000976-40-NL (EUCTR) | 04/05/202120210504 | 12/02/202120210212 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Admin ... | A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Ph ... | Alexander Disease MedDRA version: 22.1;Level: PT;Classification code 10083059;Term: Alexander disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Alexander Disease MedDRA version: 22.1;Level: PT;Classification code 10083059;Term: Alexander diseas ... | Product Name: ION373 Product Code: ION373 INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID Product Name: ION373 Product Code: ION373 INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2-M ... | Ionis Pharmaceuticals | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 42 | Phase 1;Phase 2;Phase 3 | United States;Canada;Israel;Netherlands;United Kingdom;Italy;Japan | ||
| 4 | EUCTR2020-000976-40-GB (EUCTR) | 00000000 | 28/07/202020200728 | Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Admin ... | A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexander Disease A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Ph ... | Alexander Disease MedDRA version: 22.1;Level: PT;Classification code 10083059;Term: Alexander disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] Alexander Disease MedDRA version: 22.1;Level: PT;Classification code 10083059;Term: Alexander diseas ... | Product Name: ION373 Product Code: ION373 INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2-METHOXYETHYL)-D-RIBOSE ANTISENSE OLIGONUCLEOTIDE TARGETING GLIAL FIBRILLARY ACIDIC PROTEIN MESSENGER RIBONUCLEIC ACID Product Name: ION373 Product Code: ION373 INN or Proposed INN: ION373 Other descriptive name: 2'-O-(2-M ... | Ionis Pharmaceuticals, Inc | NULL | NA | Female: yes Male: yes | 42 | Phase 1;Phase 2;Phase 3 | United States;Canada;Argentina;Australia;Israel;Netherlands;Japan;Italy;United Kingdom |